TW200505934A - Compound having affinity with calcified tissue - Google Patents

Compound having affinity with calcified tissue

Info

Publication number
TW200505934A
TW200505934A TW093107856A TW93107856A TW200505934A TW 200505934 A TW200505934 A TW 200505934A TW 093107856 A TW093107856 A TW 093107856A TW 93107856 A TW93107856 A TW 93107856A TW 200505934 A TW200505934 A TW 200505934A
Authority
TW
Taiwan
Prior art keywords
compound
affinity
group
integer
calcified tissue
Prior art date
Application number
TW093107856A
Other languages
English (en)
Inventor
Nobuhiko Kanazashi
Aki Morishita
Osamu Ito
Miki Kurami
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of TW200505934A publication Critical patent/TW200505934A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW093107856A 2003-03-26 2004-03-23 Compound having affinity with calcified tissue TW200505934A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003085919 2003-03-26

Publications (1)

Publication Number Publication Date
TW200505934A true TW200505934A (en) 2005-02-16

Family

ID=33095045

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093107856A TW200505934A (en) 2003-03-26 2004-03-23 Compound having affinity with calcified tissue

Country Status (11)

Country Link
US (1) US20060189567A1 (zh)
EP (1) EP1609797A1 (zh)
JP (1) JP4723378B2 (zh)
KR (1) KR20050109608A (zh)
CN (1) CN1764670A (zh)
AU (1) AU2004223955A1 (zh)
BR (1) BRPI0408717A (zh)
CA (1) CA2520147A1 (zh)
NO (1) NO20054914L (zh)
TW (1) TW200505934A (zh)
WO (1) WO2004085452A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9820986B2 (en) 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
CN107326674A (zh) * 2017-07-21 2017-11-07 安徽华锦柏亚纤纺科技有限公司 一种涤棉梭织物的防水防油整理方法
CN108872131A (zh) * 2018-08-16 2018-11-23 浙江诚意药业股份有限公司 一种鉴别甲壳类氨基葡萄糖和微生物法氨基葡萄糖的方法
WO2021046092A1 (en) * 2019-09-03 2021-03-11 Procypra Therapeutics, Llc A novel polymorph and uses thereof
KR20210031159A (ko) * 2019-09-11 2021-03-19 주식회사 엘지화학 리튬 이차전지용 비수전해액 및 이를 포함하는 리튬 이차전지
WO2022135381A1 (zh) * 2020-12-22 2022-06-30 浙江大学 诱导肿瘤细胞发生自发钙化的分子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750928A (en) * 1980-09-13 1982-03-25 Nippon Mejifuijitsukusu Kk Diagnostic agent for scanning bone
GB8310438D0 (en) * 1983-04-18 1983-05-25 Amersham Int Plc Bone-seeking complexes of technetium-99m
US5250702A (en) * 1988-06-07 1993-10-05 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
JP2815615B2 (ja) * 1988-06-07 1998-10-27 日本メジフィジックス株式会社 ジエチレントリアミン五酢酸誘導体とその用途
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5202109A (en) * 1988-06-10 1993-04-13 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
JP3048628B2 (ja) * 1990-11-30 2000-06-05 イハラケミカル工業株式会社 還元ヘキサ―ｎ―アセチル―キトヘキサオースを有効成分とする抗腫瘍剤
AU675166B2 (en) * 1993-10-22 1997-01-23 Nihon Medi-Physics Co., Ltd. Peptide having inflammation affinity and radioactive diagnostic containing the same
JPH07206895A (ja) * 1993-10-22 1995-08-08 Nippon Mejifuijitsukusu Kk 炎症親和性ペプチド及び該ペプチドを含有してなる放射性診断剤
JP2001114792A (ja) * 1999-10-12 2001-04-24 Nihon Medi Physics Co Ltd ビスホスホン酸誘導体およびその放射性核種標識体
IL145723A0 (en) * 2000-10-11 2002-07-25 Nihon Mediphysics Co Ltd Process for producing an amide compound
JP4185273B2 (ja) * 2000-10-11 2008-11-26 日本メジフィジックス株式会社 アミド化合物の製造方法

Also Published As

Publication number Publication date
JP4723378B2 (ja) 2011-07-13
WO2004085452A1 (ja) 2004-10-07
US20060189567A1 (en) 2006-08-24
JPWO2004085452A1 (ja) 2006-06-29
CA2520147A1 (en) 2004-10-07
CN1764670A (zh) 2006-04-26
EP1609797A1 (en) 2005-12-28
NO20054914L (no) 2005-11-03
KR20050109608A (ko) 2005-11-21
AU2004223955A1 (en) 2004-10-07
BRPI0408717A (pt) 2006-03-07

Similar Documents

Publication Publication Date Title
RU2008132204A (ru) Соединения для лечения метаболических заболеваний
UA84402C2 (ru) Применение монооксида углерода для лечения воспаления почек
WO2007006041A8 (en) Imaging and therapeutic method using monocytes
EP2253330A3 (en) Conjugated biological molecules and their preparation
NO20054914L (no) Forbindelse med affinitet til kalsifisert vev
DE60305906D1 (de) Okklusionszusammensetzung umfassend ein poly(2-cyanoacrylat)-monomer
EA200300845A1 (ru) Модифицированные антитела и способы применения
CA2530006A1 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
EP1891954A3 (en) Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EP1348706A4 (en) SUBSTITUTED THIAZOLE DERIVATIVES CARRYING 3-PYRIDYL GROUPS, PROCESS FOR THEIR PRODUCTION AND USE THEREOF
EA200300507A1 (ru) Радиофармацевтические агенты для диагностики болезни альцгеймера
PL377715A1 (pl) Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
EP2597083A3 (en) Selective hydroxamate based MMP inhibitors
Rami et al. Carbonic anhydrase inhibitors: copper (II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII
MA27056A1 (fr) Derives d'azolylcarbinols d'aryle (ou d'heteroaryle) pour le traitement de l'incontinence d'urine.
NZ543632A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2002350950A1 (en) Compounds for imaging alzheimer's disease
WO2004100998A3 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
EP1382607A3 (en) Prenyl transferase inhibitors
AU2921199A (en) 3,4-dihydroquinoline derivatives as nitrogen monoxide synthase (nos) inhibitors
ATE325624T1 (de) Moleküle für die behandlung und diagnose von tumoren
Cowley et al. Carcinoma developing in a remnant of the gallbladder